MADRID, Feb. 20, 2020 /PRNewswire/ -- Abbott (NYSE:
ABT) announced today that four real-world data
abstractsi,ii,iii,iv are being presented
during the 13th Advanced Technologies & Treatments for
Diabetes (ATTD) in Madrid. The new
data show that users of the FreeStyle Libre system have improved
glucose control,iii increased time in target glucose
range,iii and decreased time in
hyperglycemiaiv (high glucose levels) and
hypoglycemiaiv (low glucose levels), as well as
reduced HbA1Ci,ii (average glucose
levels over a three month period).ii
"As the world leader in sensor-based glucose monitoring with
more than two million users, Abbott's FreeStyle Libre system has an
unmatched body of real-world evidence supporting its clinical
benefits," said Mahmood Kazemi,
M.D., divisional vice president, global medical and scientific
affairs, and chief medical officer, Diabetes Care, Abbott. "Time
and time again, we've seen meaningful data that reaffirm our
technology's direct impact in achieving better health outcomes for
people with diabetes – and the findings at ATTD underscore how
we're continuing to transform people's lives."
The following abstracts are being presented at ATTD:
Improving HbA1c Control in People with Type 1 or Type 2
Diabetes Using FreeStyle Libre
- People living in Germany with
Type 1 or Type 2 diabetes on insulin show a sustained reduction in
HbA1c over 12 months following use of the FreeStyle Libre
system,ii which indicates that FreeStyle Libre
users had an improved HbA1c that was maintained over a substantial
period of time. The American Diabetes Association recommends an
HbA1C goal of less than 7% for adults with
diabetes.v People with Type 1 diabetes using the
FreeStyle Libre system with a baseline HbA1c greater than 7.5%
showed an average reduction of 1.4%, and people with Type 2
diabetes showed an average reduction of 1.2%. An HbA1c level
that is reduced by almost 1% is linked to an overwhelming reduction
in long-term complications of diabetes by 30% according to landmark
studies.vi
Real-World Study of FreeStyle Libre System Among Adults with
Type 1 and Type 2 Diabetes within the Sweden National Diabetes
Register
- Notable datai from Sweden's National Diabetes
Register conclude that people with Type 1 and Type 2 diabetes
significantly reduced their HbA1c when they used the FreeStyle
Libre system for three to nine months. A reduction
of HbA1c of 0.44% for people with Type 1 and 0.67% for
people with Type 2 were observed with first-time users of FreeStyle
Libre system.
Canadian Real-World Analysis of FreeStyle Libre and Glycemic
Control
- Expanded analysisiii of real-world data from
Canada demonstrate that higher
frequency of scanning is associated with increased time in target
glucose range (hours per day spent in between 70-180
mg/dLvii) and decreased hypoglycemia. Greater time in
range has been linked
to more stable glucose control, which could
lead to fewer complications. FreeStyle Libre users who scanned at
the lowest frequency (3.3 scans per day) spent 54.6% time in
range, and users with the highest scanning frequency (29.3
scans per day) spent 66.7% time in range.
This analysis, in addition to previous real-world
findings,viii consistently show a strong
association between FreeStyle Libre users who scan more frequently
and overall improved glucose control.
Continuous Glucose Monitoring (CGM) Use in the U.S. is
Associated with Reduction in Acute Diabetes Complications, Even
with Prior Low Test Strip Use
- More than 12,000 people with diabetes using a CGM for the first
time, including the FreeStyle Libre system, experienced a
significant reduction in acute diabetes
complicationsiv-- even in people with diabetes that have
a history of self-monitoring of blood glucose (SMBG) using less
than four test strips per day.ix People with Type 1
diabetes experienced a significant reduction in acute diabetes
complications of 44% after CGM usage.iv For people
with Type 2 diabetes, there was a significant reduction of
51%.iv
Abbott's FreeStyle Libre system is now being used by more than 2
million people living with diabetes across 46
countries.x Abbott has secured partial or full
reimbursement for the FreeStyle Libre system in 36 countries,
including France, Ireland, Japan, the United
Kingdom, and the U.S.
About FreeStyle Libre System
Abbott's FreeStyle Libre
system, the world leading sensor-based glucose monitoring
technology,xi is designed to change how people with
diabetes measure their glucose levels and ultimately help them
achieve better health outcomes.xii The system reads
glucose levels through a sensor that can be worn on the back of the
upper arm, eliminating the need for finger
sticks.xiii
For the U.S., important safety information:
https://www.freestylelibre.us/safety-information.html
About Abbott
Abbott is a global healthcare leader that
helps people live more fully at all stages of life. Our portfolio
of life-changing technologies spans the spectrum of healthcare,
with leading businesses and products in diagnostics, medical
devices, nutritionals and branded generic medicines. Our 107,000
colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
i Real-world study of FreeStyle Libre system
among adults with Type 1 and Type 2 diabetes within the Swedish
National Diabetes Register; Katarina Eeg-Olofsson, Ann-Marie Svensson, Stefan Franzén, Hodan Ahmed Ismail, Michael Törnblom,
Fleur Levrat-Guillen
ii Improving HbA1c control in people with Type 1 or
Type 2 diabetes using flash glucose monitoring: a retrospective
observational analysis in two German centers; Gerhard Klausmann, Ludger Rose, Alexander
Seibold
iii Canadian real-world analysis of flash glucose
monitoring and glycemic control; Lori
Berard, Laura Brandner
iv Acute diabetes complications defined by
hypoglycemia, hypoglycemic coma, hyperglycemia, ketoacidosis, or
hyperosmolarity ICD-10 codes as primary diagnosis for inpatient or
as any position in the outpatient emergency claim; Matthew Kerr, Gregory
Roberts, Diana Souto,
Yelena Nabutovsky
v American Diabetes Association (ADA),
https://www.diabetes.org/a1c
vi The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus, The New England Journal of
Medicine, September 30, 1993,
Volume 329, Number 14
vii ADA, International Consensus on Time-In-Range.
The group recommends a target range of 70-180 mg/dL [3.9-10.0
mmol/L] for individuals with Type 1 diabetes and Type 2 diabetes,
and 63-140 mg/dL [3.5-7.8 mmol/L] during pregnancy, along with a
set of targets for the time per day
viii Expanded real-world use confirms strong
association between frequency of flash glucose monitoring and
glucose control. Presented at the 12th Advanced Technologies &
Treatments for Diabetes (ATTD) in Berlin,
Germany; Lang, SR Jangam
ix Compared outcomes before and after purchase of
continuous glucose monitoring
x Data on file, Abbott Diabetes Care
xi Data on file, Abbott Diabetes Care. Data based
on the number of users worldwide for the FreeStyle Libre system
compared to the number of users for other leading personal use,
sensor-based glucose monitoring systems
xii Bolinder, Jan, et al. Novel glucose-sensing
technology and hypoglycemia in Type 1 diabetes: a multi-center,
non-masked, randomized controlled trial. The Lancet
388.10057 (2016): 2254-2263
xiii A fingerstick test using a glucometer is
required during times of rapidly changing glucose levels when
interstitial fluid glucose levels may not accurately reflect blood
glucose levels; or if hypoglycemia or impending hypoglycemia is
reported by the system; or when symptoms do not match the system
readings
View original
content:http://www.prnewswire.com/news-releases/new-real-world-data-show-that-abbotts-freestyle-libre-system-delivers-positive-health-outcomes-for-people-with-type-1-and-type-2-diabetes-301007694.html
SOURCE Abbott